Literature DB >> 19526406

Are patients getting the "gist" in risk communication? Patient understanding of prognosis in breast cancer treatment.

David W Hutton1, Jeffrey K Belkora, Ross D Shachter, Dan H Moore.   

Abstract

BACKGROUND: Many oncologists consult the Adjuvant! prognostic model to communicate risk with breast cancer patients; however, little is known about how effective that communication is.
METHODS: The authors analyzed this small data set featuring 20 breast cancer patients' risk estimates, focusing on rankings or gist of the estimates.
RESULTS: Overall, there was no gain in the accuracy of patient rankings. The number of patients with more accurate estimates was matched by the number of patients with less accurate estimates after consultation.
CONCLUSIONS: The current methods used by oncologists to present Adjuvant! risks were not effective in helping patients to get the gist of their risks.

Entities:  

Mesh:

Year:  2009        PMID: 19526406     DOI: 10.1080/08858190902876452

Source DB:  PubMed          Journal:  J Cancer Educ        ISSN: 0885-8195            Impact factor:   2.037


  13 in total

1.  Fuzzy-trace theory, risk communication, and product labeling in sexually transmitted diseases.

Authors:  Valerie F Reyna; Mary B Adam
Journal:  Risk Anal       Date:  2003-04       Impact factor: 4.000

2.  Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.

Authors:  P M Ravdin; I A Siminoff; J A Harvey
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  The role of risk and benefit perception in informed consent for surgery.

Authors:  A Lloyd; P Hayes; P R Bell; A R Naylor
Journal:  Med Decis Making       Date:  2001 Mar-Apr       Impact factor: 2.583

4.  Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Authors:  Ivo A Olivotto; Chris D Bajdik; Peter M Ravdin; Caroline H Speers; Andrew J Coldman; Brian D Norris; Greg J Davis; Stephen K Chia; Karen A Gelmon
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

5.  Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information.

Authors:  Pamela B Peele; Laura A Siminoff; Ying Xu; Peter M Ravdin
Journal:  Med Decis Making       Date:  2005 May-Jun       Impact factor: 2.583

6.  Misunderstanding in cancer patients: why shoot the messenger?

Authors:  M Gattellari; P N Butow; M H Tattersall; S M Dunn; C A MacLeod
Journal:  Ann Oncol       Date:  1999-01       Impact factor: 32.976

7.  Distress, psychiatric syndromes, and impairment of function in women with newly diagnosed breast cancer.

Authors:  Mark T Hegel; Caroline P Moore; E Dale Collins; Stephen Kearing; Karen L Gillock; Raine L Riggs; Kate F Clay; Tim A Ahles
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

Review 8.  The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research.

Authors:  Hope S Rugo; Tim Ahles
Journal:  Semin Oncol       Date:  2003-12       Impact factor: 4.929

Review 9.  Communicating evidence for participatory decision making.

Authors:  Ronald M Epstein; Brian S Alper; Timothy E Quill
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

10.  Cognitive function in breast cancer patients prior to adjuvant treatment.

Authors:  Tim A Ahles; Andrew J Saykin; Brenna C McDonald; Charlotte T Furstenberg; Bernard F Cole; Brett S Hanscom; Tamsin J Mulrooney; Gary N Schwartz; Peter A Kaufman
Journal:  Breast Cancer Res Treat       Date:  2007-08-03       Impact factor: 4.872

View more
  9 in total

Review 1.  Decision making and cancer.

Authors:  Valerie F Reyna; Wendy L Nelson; Paul K Han; Michael P Pignone
Journal:  Am Psychol       Date:  2015 Feb-Mar

2.  Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication?

Authors:  Jeffrey K Belkora; David W Hutton; Dan H Moore; Laura A Siminoff
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

3.  Medical barriers to mammography screening of African American women in a high cancer mortality area: implications for cancer educators and health providers.

Authors:  Rosalie F Young; Kendra Schwartz; Jason Booza
Journal:  J Cancer Educ       Date:  2011-06       Impact factor: 2.037

4.  The benefits of discussing adjuvant therapies one at a time instead of all at once.

Authors:  Brian J Zikmund-Fisher; Andrea M Angott; Peter A Ubel
Journal:  Breast Cancer Res Treat       Date:  2010-10-14       Impact factor: 4.872

5.  Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy.

Authors:  Isaac M Lipkus; Ellen Peters; Gretchen Kimmick; Vlayka Liotcheva; Paul Marcom
Journal:  Med Decis Making       Date:  2010-02-16       Impact factor: 2.583

6.  Physicians' perceptions of the value of prognostic models: the benefits and risks of prognostic confidence.

Authors:  Sarah A M Hallen; Norbert A M Hootsmans; Laura Blaisdell; Caitlin M Gutheil; Paul K J Han
Journal:  Health Expect       Date:  2014-05-12       Impact factor: 3.377

7.  Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy.

Authors:  Clara N Lee; Matthew H Wetschler; Yuchiao Chang; Jeffrey K Belkora; Beverly Moy; Ann Partridge; Karen R Sepucha
Journal:  BMC Med Inform Decis Mak       Date:  2014-08-20       Impact factor: 2.796

8.  Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.

Authors:  Jeffrey K Belkora; Hope S Rugo; Dan H Moore; David W Hutton; Daniel F Chen; Laura J Esserman
Journal:  BMC Cancer       Date:  2009-04-28       Impact factor: 4.430

9.  The value of personalised risk information: a qualitative study of the perceptions of patients with prostate cancer.

Authors:  Paul K J Han; Norbert Hootsmans; Michael Neilson; Bethany Roy; Terence Kungel; Caitlin Gutheil; Michael Diefenbach; Moritz Hansen
Journal:  BMJ Open       Date:  2013-09-13       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.